Cell Culture Media for Vaccines Witnesses Traction with Emergence of Covid-19

 

Cell culture media generally comprise an appropriate source of energy and compounds which regulate the cell cycle. There are three major types of cell culture, which include: primary cell culture, secondary cell culture, and cell line. Recently there has been an enormous media focus on cell culture media for vaccines with the emergence of Covid-19. In the U.S., from 3 January 2020 to 6:08 pm CEST, 5 August 2021, there have been 35,125,227 confirmed cases of COVID-19 with 609,613 deaths, reported to WHO. As of 29 July 2021, a total of 345,727,128 vaccine doses have been administered.


One important aspect of cell culture media for vaccines is accurate data collection. Thus, all aspects of vaccine development will require accurate data collection and reporting. In addition, accurate data is needed to test for the impact of potential vaccines on public health. Finally, accurate data is needed for surveillance of progress in fighting disease. Although some countries have introduced routine surveillance of vaccine-associated cases, large gaps remain between incidence and real-time management.


The increasing use of cell culture media for the global vaccine market must be monitored to ensure that vaccines are produced at adequate levels. To address these issues, manufacturers must incorporate stringent quality control measures into production schedules. These measures include ensuring that adequate supplies of proteins, cells, and vaccines are made available. Simultaneously, it is essential to track and update the manufacturing records of vaccines that have already been released into the market.


The market for cell culture media is witnessing several M&A activities. In July 2021, Sartorius, a major player in the life science products market, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.